Breast Cancer
Conditions
Interventions
Steroidal AI group:Exemestane
Non-steroidal AI group:Letrozole or anastrozole
Sponsors
The First Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 50-70 years, conforming to the criteria determining menopause in accordance with NCCN guideline; 2. Meet the standard of positive hormone receptor; 3. Early breast cancer; 4. Patients receiving adjuvant AI therapy after radical mastectomy for breast cancer; 5. An Eastern Cooperative Oncology Group (ECOG) score <=1; 6. Developing critical lipid abnormalities at 1 dose of administration; 7. Provision of written informed consent.
Exclusion criteria
Exclusion criteria: 1. History of liver and kidney damage or history of digestive ulcers; 2. Those who have received endocrine therapy in the past; 3. Allergy to AIs; 4. Those who are unable to complete the expected trial due to other diseases; 5. Factors that have a significant impact on oral drug absorption; 6. Other serious physical or psychiatric illnesses or laboratory abnormalities, which may be worsened by participation in this trial or may interfere with the results of this trial. Upon the request of the investigators for safety reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with dyslipidemia;5-year DFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in blood lipid levels;5-year OS after AI therapy; | — |
Countries
China
Contacts
Public ContactFeng Jin
The First Hospital of China Medical University
Outcome results
None listed